Key Takeaways
- Meiogenix has formed a scientific and industry advisory board comprising experts from Monsanto, Corteva, CoverCress, Cornell University, Aramis Biotech, and CNRS.
- The board brings more than a century of combined experience across genetics, plant breeding, and commercialization.
- The advisory board will guide deployment of Meiogenix’s targeted recombination platform, designed to accelerate development of resilient, high-performing crop varieties.
- Precision-guided recombination offers a non-GMO path for enhancing traits such as disease resistance, stress tolerance, and climate adaptability.
- Board members are expected to support partnership expansion across global seed companies and crop categories.
Meiogenix Announces Advisory Board of Global Leaders in Plant Breeding and Genetics
Meiogenix, a biotechnology company focused on epigenetics and AI-enabled precision breeding, has appointed a high-profile advisory board to support the rollout of its targeted recombination technology. The board includes senior scientific and commercial leaders whose backgrounds span trait discovery, crop genetics, and large-scale seed innovation.
The newly formed advisory board unites experts with experience at organizations such as Monsanto, Corteva, CoverCress, Cornell University, Aramis Biotech, and France’s CNRS. Collectively, they bring decades of insight into how advanced genetics can be translated into commercially viable, grower-ready crop varieties.
“Assembling this group is a defining moment for Meiogenix,” said Ricardo Garcia de Alba, CEO of Meiogenix. “These are the leaders who shaped modern seed innovation. Their counsel ensures that our science translates into a global breeding platform redefining what’s possible, delivering genetic diversity faster, more predictably, and using untapped genetic resources.”
Targeted Recombination Positioned as a Next Step in Precision Breeding
The advisory board will guide further deployment of Meiogenix’s targeted recombination platform, which enables plant breeders to unlock natural genetic diversity more effectively. The technology supports non-GMO development of enhanced traits including disease resistance, environmental resilience, and improved productivity.
According to the company, precision-guided recombination offers a scalable path to developing climate-adapted varieties that meet market demands at a faster pace. As Meiogenix expands its technology applications, the board is expected to help strengthen collaborations with seed companies across row crops, vegetables, and specialty crops.
“Meiogenix represents the most significant advance in targeted recombination since it was first described nearly a century ago,” said Neal Gutterson, Chairman of the Board and leader of the advisory board. “By accessing previously unavailable natural genetic diversity, Meiogenix is reinventing how we breed for resilience, productivity, and sustainability.”
Meiogenix Advisory Board Members
Scientific and Industry Expertise
- Dr. Neal Gutterson – CGIAR System Board; Partner & CTO at Radicle Growth; Former CTO at Corteva and DuPont Pioneer; Chairman of the Board, Meiogenix
- Dr. Marc Albertsen – Former Director of Trait Discovery, Corteva Agriscience
- Marc André D’Aoust – Co-Founder and CSO, Aramis Biotech
- Dr. Marlin Edwards – Former Chief Technology Officer, Monsanto Seeds
- Dr. Alain Nicolas – CNRS Research Director, Group Leader, Institut Curie
- Dr. Wojtek Pawlowski – Professor of Plant Genetics and Plant Breeding, Cornell University
- Jerry Steiner – Former CEO, CoverCress; Former EVP, Sustainability & Corporate Affairs, Monsanto
